
1. cell. 2016 sep 8;166(6):1471-1484.e18. doi: 10.1016/j.cell.2016.07.029.

induction hiv neutralizing antibody lineages mice diverse precursor
repertoires.

tian m(1), cheng c(2), chen x(2), duan h(2), cheng hl(1), dao m(1), sheng z(3),
kimble m(1), wang l(2), lin s(1), schmidt sd(2), du z(1), joyce mg(2), chen y(1),
dekosky bj(2), chen y(1), normandin e(2), cantor e(1), chen re(2), doria-rose
na(2), zhang y(2), shi w(2), kong wp(2), choe m(2), henry ar(2), laboune f(2),
georgiev is(4), huang py(1), jain s(1), mcguire at(5), georgeson e(6), menis
s(6), douek dc(2), schief wr(7), stamatatos l(5), kwong pd(2), shapiro l(8),
haynes bf(9), mascola jr(10), alt fw(11).

author information: 
(1)program cellular molecular medicine, boston children's hospital, howard
hughes medical institute, boston, 02115, usa; department genetics, harvard 
medical school, boston, 02115, usa.
(2)vaccine research center, national institute allergy infectious
diseases, bethesda, md 20892, usa.
(3)department biochemistry molecular biophysics department systems 
biology, columbia university, new york, ny 10032, usa.
(4)vanderbilt vaccine center, vanderbilt university, nashville, tn 37232, usa.
(5)fred hutchinson cancer research center, seattle, wa 02129, usa.
(6)department immunology microbial science iavi neutralizing antibody 
center, scripps research institute, la jolla, ca 92037, usa.
(7)department immunology microbial science iavi neutralizing antibody 
center, scripps research institute, la jolla, ca 92037, usa; ragon institute 
of massachusetts general hospital, massachusetts institute technology,
cambridge, 02129, usa; harvard university, cambridge, 02129, usa.
(8)vaccine research center, national institute allergy infectious
diseases, bethesda, md 20892, usa; department biochemistry molecular
biophysics department systems biology, columbia university, new york, ny
10032, usa.
(9)duke human vaccine institute, duke university school medicine, durham, nc
27710, usa.
(10)vaccine research center, national institute allergy infectious
diseases, bethesda, md 20892, usa. electronic address: jmascola@mail.nih.gov.
(11)program cellular molecular medicine, boston children's hospital,
howard hughes medical institute, boston, 02115, usa; department genetics,
harvard medical school, boston, 02115, usa. electronic address:
alt@enders.tch.harvard.edu.

comment in
    cell. 2016 sep 8;166(6):1360-1.
    trends mol med. 2017 jan;23 (1):1-3.

the design immunogens elicit broadly reactive neutralizing antibodies
(bnabs) major obstacle hiv-1 vaccine development. one approach to
assess potential immunogens use mice expressing precursors human bnabs
as vaccination models. bnabs vrc01-class derive ighv1-2
immunoglobulin heavy chain neutralize wide spectrum hiv-1 strains via
targeting cd4 binding site envelope glycoprotein gp120. now
describe mouse vaccination model allows germline human ighv1-2(∗)02
segment undergo normal v(d)j recombination and, thereby, leads the
generation peripheral b cells express highly diverse repertoire of
vrc01-related receptors. sequentially immunized modified gp120
glycoproteins designed engage vrc01 germline intermediate antibodies,
ighv1-2(∗)02-rearranging mice, also express vrc01-antibody precursor
light chain, support affinity maturation vrc01 precursor antibodies
into hiv-neutralizing antibody lineages.

copyright © 2016 elsevier inc. rights reserved.

doi: 10.1016/j.cell.2016.07.029 
pmcid: pmc5103708
pmid: 27610571  [indexed medline]

